Background and purpose: A planning target volume (PTV) in photon treatments aims to ensure that the clinical target volume (CTV) receives adequate dose despite treatment uncertainties. The underlying static dose cloud approximation (the assumption that the dose distribution is invariant to errors) is problematic in intensity modulated proton treatments where range errors should be taken into account as well. The purpose of this work is to introduce a robustness evaluation method that is applicable to photon and proton treatments and is consistent with (historic) PTV-based treatment plan evaluations. Materials and methods: The limitation of the static dose cloud approximation was solved in a multiscenario simulation by explicitly calculating doses for various treatment scenarios that describe possible errors in the treatment course. Setup errors were the same as the CTV-PTV margin and the underlying theory of 3D probability density distributions was extended to 4D to include range errors, maintaining a 90% confidence level. Scenario dose distributions were reduced to voxel-wise minimum and maximum dose distributions; the first to evaluate CTV coverage and the second for hot spots. Acceptance criteria for CTV D98 and D2 were calibrated against PTV-based criteria from historic photon treatment plans. Results: CTV D98 in worst case scenario dose and voxel-wise minimum dose showed a very strong correlation with scenario average D98 (R 2 > 0.99). The voxel-wise minimum dose visualised CTV dose conformity and coverage in 3D in agreement with PTV-based evaluation in photon therapy. Criteria for CTV D98 and D2 of the voxel-wise minimum and maximum dose showed very strong correlations to PTV D98 and D2 (R 2 > 0.99) and on average needed corrections of À0.9% and +2.3%, respectively. Conclusions: A practical approach to robustness evaluation was provided and clinically implemented for PTV-less photon and proton treatment planning, consistent with PTV evaluations but without its static dose cloud approximation. Ó 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 141 (2019) 267-274 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a b s t r a c t
Background and purpose: A planning target volume (PTV) in photon treatments aims to ensure that the clinical target volume (CTV) receives adequate dose despite treatment uncertainties. The underlying static dose cloud approximation (the assumption that the dose distribution is invariant to errors) is problematic in intensity modulated proton treatments where range errors should be taken into account as well. The purpose of this work is to introduce a robustness evaluation method that is applicable to photon and proton treatments and is consistent with (historic) PTV-based treatment plan evaluations. Materials and methods: The limitation of the static dose cloud approximation was solved in a multiscenario simulation by explicitly calculating doses for various treatment scenarios that describe possible errors in the treatment course. Setup errors were the same as the CTV-PTV margin and the underlying theory of 3D probability density distributions was extended to 4D to include range errors, maintaining a 90% confidence level. Scenario dose distributions were reduced to voxel-wise minimum and maximum dose distributions; the first to evaluate CTV coverage and the second for hot spots. Acceptance criteria for CTV D98 and D2 were calibrated against PTV-based criteria from historic photon treatment plans. Results: CTV D98 in worst case scenario dose and voxel-wise minimum dose showed a very strong correlation with scenario average D98 (R 2 > 0.99). The voxel-wise minimum dose visualised CTV dose conformity and coverage in 3D in agreement with PTV-based evaluation in photon therapy. Criteria for CTV D98 and D2 of the voxel-wise minimum and maximum dose showed very strong correlations to PTV D98 and D2 (R 2 > 0.99) and on average needed corrections of À0.9% and +2.3%, respectively. Conclusions: A practical approach to robustness evaluation was provided and clinically implemented for PTV-less photon and proton treatment planning, consistent with PTV evaluations but without its static dose cloud approximation. The use of margins in photon radiotherapy is a long established and universally adopted method to provide adequate target coverage under the presence of uncertainties. The CTV-PTV margin provides a geometrical buffer zone around the target within which the desired dose is achieved for the majority of treatments; criteria of 95% of the prescription dose in 90% of the patient population has found general appeal [1, 2] . The suitability of a geometricallyexpanded buffer zone arises from the (relative) insensitivity of megavoltage photon dose distributions to density changes in the beam path. By and large, the biggest risk to a photon dose distribution is a geometrical miss -a translation of the CTV relative to the beam. Therefore, the static dose cloud approximation (dose distribution is invariant to errors) inherent in the PTV concept, while not perfect, has worked well [3] .
This fundamental assumption is not valid for proton therapy (PT) [4, 5] due to the relationship between the proton range and the medium-dependent stopping power. On top of the inherent uncertainties in predicting the stopping power [6, 7] , errors in proton range arise from beam path density changes due to patient setup or anatomy differences [8] . This range uncertainty has been addressed by range adapted PTVs, where an extra margin is added to the distal portion of the PTV in the beam path. This works reasonably well for delivery techniques where the dose is uniform for each of the beams [9] . With the advent of pencil beam scanning, intensity modulated or multi-field optimised proton therapy (IMPT) became widely available [10] . Just as its intensity https://doi.org/10.1016/j.radonc.2019.08.005 0167-8140/Ó 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). modulated photon radiotherapy counterpart, this technique allows uniform target coverage to be achieved using non-uniform beam doses, leading to potentially steep inter-beam dose gradients patched together within the target. This is where the use of a geometric buffer zone breaks down, as now the range uncertainties can lead to dose differences within the CTV itself and not just at the periphery [11] .
One method which has been developed to overcome the limitations of the static dose cloud approximation is robust optimisation, whereby deviations from the nominal (i.e. error-free) dose distribution are calculated explicitly for each scenario and minimised through the use of planning objectives [12] [13] [14] . A scenario is commonly called 'error scenario', although in this work terminology 'treatment scenario' is used, see next section. Since becoming available in commercial treatment planning systems, robust optimisation has demonstrated the ability to improve target coverage robustness and/or organ at risk (OAR) sparing compared to PTV-based planning, in both proton [15] [16] [17] [18] [19] [20] [21] and photon therapy [22] [23] [24] [25] . It must be noted however, that robust target coverage is generally one of many variables in the optimisation objective function and therefore is in competition with other objectives, such as OAR dose. Therefore, there must be some evaluation of the optimised plan that quantifies whether coverage criteria have been satisfied under the specified uncertainty conditions. In PTV-based planning there are established metrics for target coverage, such as PTV V95% ! 98% prescription dose [26] , which ensures a certain probability of tumour control as well as consistency of practice and dose reporting world-wide. There is currently no such established metric for reporting on plan robustness, the consequence being that any two treatment plans with similar target coverage in the nominal scenario may behave very differently in the scenarios. One could assess the dose distribution of each scenario but in clinical practice this is unfeasible. Methods of summarising the dose deviations in the scenarios have been investigated, including the use of dose volume histogram uncertainty bands [27] [28] [29] , errorbar distributions [30] and root-mean-square volume histograms [16] . While each of these methods are useful for relative comparisons of robustness, clearly defined target coverage acceptance criteria, such as V95% ! 98% for the PTV, are lacking and while error-bar distributions provide 3D spatial information of where local dose deviations may occur, it is not clear how coverage can be assessed in a PTV-like way. These limitations are not trivial and lead to difficulties for physicians and physicists to assess the quality of a robustly optimised plan. Furthermore, without an established robustness metric, consistent with PTV-based evaluation, how can the quality of PTV-based treatment plans be compared to robustly optimised plans, especially in proton therapy where the PTV concept is no longer adequate? This question is particularly relevant in the new era of model-based patient selection whereby the effectiveness of different treatment modalities is compared. In the Dutch system, PT can be indicated if a significant clinical benefit can be expected relative to conventional photon treatments; in this case, a difference in the normal tissue complication probability (NTCP) [31, 32] . However, in order for this comparison to be fair, the target coverage must be comparable.
The aim of this work is to introduce a robustness evaluation method that addresses the two main issues highlighted above: (i) overcome the limitations of current robustness evaluation methods, and (ii) ability to universally compare target coverage under uncertainties for any treatment modality (i.e. photons and protons) without the use of a PTV. Perhaps most importantly, the proposed method is consistent with current PTV practice, which provides continuity for a radiotherapy community that relies heavily on PTV-based clinical data [1, 26, 33] .
Materials and methods

Outline and terminology
The scenario-based evaluation consists of the following steps:
i. Scenario-based evaluation method: treatment scenarios are created by sampling deviations from the generated treatment plan. The dose distribution is calculated for each treatment scenario. ii. Evaluation dose distribution: Scenario dose distributions are combined into evaluation dose distributions (described below), so as to provide concise information for daily clinical decision making. iii. Acceptance criteria calibration: Dose metrics are evaluated based on acceptance criteria, defined in a calibration procedure using a set of historic treatment plans.
Scenario-based evaluation method
Following the definition of Tilly [34] , a treatment scenario describes a fractionated treatment with a systematic setup error and for each fraction a random setup error. In view of computational demands, sparse sampling is used, i.e. robustness is determined for only a limited number of well-chosen worst-case scenarios. More specifically, errors are drawn from known probability distributions and sampled at a 90% confidence level, as commonly used in CTV-PTV margin recipes [2] and close to the value of 85% proposed in [35] .
Setup errors are modelled as rigid, uncorrelated, and normally distributed 3D translations of the planning CT, with standard devi- 2 , we find that r 3 = 2.5 corresponds to a 90% confidence level ( Fig. 1) with r 3 the length of the error vector in 3D.
Random variations in patient setup r, resulting in dose blurring and shrinkage of the volume treated to 95% of the prescribed dose (i.e. the V95%), are taken into account as an additional systematic contribution. Following [2] : M = 2.5R + 1.64 p (r 2 + r p 2 ) -1.64 r p with r p the penumbra width, for r p = 3.2 mm, the systematic shift of the 95% isodose line caused by random variations can be approximated by 0.7r. This way, again for computational efficiency, a multi-fraction treatment scenario is approximated as a treatment with only a systematic setup error.
Variations other than rigid setup errors, such as non-rigid deformations, anatomical changes, intrafraction motion [36] and rotations (to the extent that they are not accounted for by translations) are beyond the scope of this paper.
Under the static dose cloud assumption, the scenario-based approach is equivalent to a PTV-based evaluation, as illustrated in Fig. 2 , and previously found by Harrington [37] .
For PT, range errors must also be taken into account, usually modelled by scaling HUs of the planning CT. Assuming that range errors (d) are not correlated with setup errors and are normally distributed, range and setup errors can be combined into a 4D Gaussian distribution r 4 2 
where R d is the standard deviation of range errors ( Fig. 1 ). Here we find that r 4 = 2.8 corresponds to a 90% confidence level, with r 4 the length of the error vector in 4D. Some relevant combinations of setup and range errors are listed in Fig. 1d . It is recommended to use the same setup errors in treatment scenarios for protons and photons, provided both modalities have comparable setup accuracy. From Fig. 1d , it can be seen that the range error should then be reduced from the common value of 1.5 to 1.24 times the standard deviation to keep the confidence level at 90%. For example, a 3.5% range error that corresponds to d/Rd = 1.5 reduces to 2.9%, an adjustment that is less than differences in clinical practice between institutes [6] . An example set of 14 treatment scenarios with rigid shifts of the planning CT, corresponding to directions defined on a cube, is shown in Fig. 3 . Adding positive and negative range errors to each setup error results in 28 scenarios for protons and 14 for photons. For each treatment scenario a dose distribution is calculated, which is referred to as the scenario dose.
Evaluation dose distribution
In order to provide meaningful yet simple methods to guide plan assessment in daily clinical practice, the multiple scenario dose distributions can be 'summarised' into an evaluation dose distribution. For example, the voxel-wise minimum dose [38] is the composite of minimum dose values per voxel from all scenarios ( Fig. 4b) . Alternatives include the voxel-wise mean dose , to points in between (12 blue dots), and combinations of these that result in 14 or 26 directions. The magnitude of the shift is equal to the error radius r3 as described in Fig. 1 . The sizes of the box in x, y, and z directions may be chosen anisotropic to reflect that in case of anisotropic setup uncertainties shifts in certain directions are more likely than in other directions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) ( Fig. 4c ) or to simply select the worst-case scenario dose, i.e. the dose of the scenario with worst CTV coverage (Fig. 4a ). For each type of evaluation dose distribution, its suitability for assessment of target coverage was determined by investigating the correlation between the CTV V95% (or D98) to the average V95 (or D98) of all treatment scenarios. This was done for 842 proton and 150 photon plans (supplement). The voxel-wise maximum dose is another evaluation dose distribution which is more suited to identifying potential hot spots.
Acceptance criteria calibration
The transition from PTV-based to scenario-based evaluation imposes the risk of introducing a systematic change in patient treatment. This can be resolved by a calibration procedure in which correlations between evaluation parameters for both methods are analysed for a set of historic treatment plans. In conventional radiotherapy, PTV V95% ! 98% is commonly used [26] . McGowan et al. [39] created a database with metrics of historically treated patients as reference for new patient plans. Following a similar approach, correlations between the PTV-and scenario-based metrics were determined for conversion of established acceptance criteria to the new evaluation metrics for various photon cases (5 lung, 6 oesophagus, 8 breast and chest wall, 24 head and neck and 13 other indications).
Results
Target coverage in each of the three types of evaluation dose distributions showed high correlations using the CTV D98 metric ( Table 1 and Figs. S3, S4b) , with a slope close to unity for both photon and proton plans. In comparison, the V95 loss metric showed weaker correlations and slopes that varied between the different evaluation distributions and modalities (Figs. S1, S4a) . The variation in slopes can be explained by the way these dose distributions are constructed ( Fig. S2 ). Of these, the voxel-wise minimum dose correlated best for both modalities (R 2 0.684 and 0.822 for proton and photon plans, respectively).
Qualitatively, evaluation of the CTV coverage in the voxel-wise minimum dose generally showed good agreement with PTV evaluations in the nominal dose distribution in slice-by-slice reviews (conceptually explained in Fig. 2 and demonstrated on patient examples in Fig. 5a, 5b) . As a consequence, the voxel-wise minimum CTV D98 metric was clinically introduced for target coverage assessment and used in the second part of this study. The voxel-
Worst scenario
Voxel-wise min dose Voxel-wise mean dose Fig. 4 . Example of the worst scenario dose, voxel wise minimum dose and voxel-wise mean dose for three scenarios (left column, higher values and brighter colours correspond to higher dose) and a photon treatment of an oropharynx patient (CTV in blue and 95% isodose in yellow). The worst scenario is a single scenario that is selected based on CTV dose metrics (e.g. lowest D98), the voxel-wise minimum is a composite of lowest dose per voxel in all scenarios, the voxel-wise mean dose is the scenario average dose per voxel. The worst scenario shows how tight the dose is only on one side of the target (in one scenario), the voxel-wise min dose shows a conformal dose whereas the voxel-wise mean dose does not correctly show how tightly the dose was planned. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) wise maximum dose evaluations indicated possible dose increases in cases with severe density inhomogeneities, like VMAT in the thoracic region, also shown in Fig. 5b . Fig. 5c shows examples of calibration of CTV D98 criteria of the voxel-wise minimum dose against D98 in PTV evaluations for various indications. A strong correlation was found with a slope just 0.9% below unity. Voxel-wise maximum dose calibration against D2 in PTV-based evaluation showed a strong correlation as well with a slope 2.3% above unity (Fig. 5d ). Scenario-based evaluations increased D2-D98 inhomogeneity by about 3%, due to the effect of setup error on dose variations.
Discussion
Scenario-based robustness evaluation improved accuracy by removing the static dose cloud approximation in PTV-based evaluation and kept consistency with historic PTV-based evaluations. D98 of three types of evaluation dose distributions (voxel-wise minimum, voxel-wise mean and worst scenario) were found to be highly correlated with scenario average metrics. Of these, the voxel-wise minimum dose was selected as it provided valuable spatial information, such as conformity of the high dose to the target, and allowed clinicians to judge the clinical significance of any under-dosage just as with the traditional PTV approach. The voxelwise maximum dose showed locations of possible hot spots in the target and can also be used for serial type OARs (e.g. spinal cord and optical nervous system) to replace planning at risk volume evaluations recommended by the ICRU.
For voxel-wise minimum and voxel-wise maximum dose distributions, only small corrections to PTV-based criteria were needed, which was defined in a calibration procedure (Figs. 5c, Fig. 5d ). This indicates that in photon treatments the static dose cloud approximation is largely true. In terms of model-based patient selection, the calibration allowed an un-biased comparison of organ at risk doses between proton and photon plans under comparably robust target coverage. As such, it forms the basis of the Dutch national consensus guidelines for proton plan evaluation. For practical reasons it was chosen to allow using PTV-based evaluation for photon plans and scenario-based evaluation in proton plans. Ideally robustness evaluation is performed as the standard method in both photon and proton planning since then results can be compared directly. In a transition phase from PTV-based to scenario-based evaluation in photon planning one could perform both evaluations to (i) gain familiarity and confidence in scenario-based evaluation and (ii) to obtain data for the calibration method.
A challenge is that scenario-based evaluation is computationally more expensive than PTV-based evaluation where speed is essential in a busy clinic. To keep calculation times clinically acceptable, several approximations were made:
Monotonous increase of dosimetric errors with setup error size was assumed and no 'intermediate' scenarios were included. Although Casiraghi et al. found that, for IMPT, scenarios at cut-off values were representative [40] , it is recommended to verify this per treatment site. Random setup errors were converted into systematic errors for protons the same way as for photons, based on penumbra width r p . Although proton and photon beams may have comparable penumbras, proton penumbras vary between machines and with airgap for range shifter beams. As random errors cause dose blurring, hot-spots will reduce in magnitude, and for evaluation of risk of hot-spots the setup error shift should be reduced. McKenzie et al. proposed a margin of 1.3R that was either reduced or increased with 0.5r to include the effect of dose blurring [41] .
These approximations may be accounted for by acceptance criteria adjustment in the calibration procedure.
Sensible error magnitudes should be defined per institution specific to their own circumstances, as these depend on patient setup protocols and CT calibration method. In this way the calibration to current PTV methods will result in target coverage criteria that are neither too strict nor too loose.
A limitation of the voxel-wise minimum and maximum dose evaluation is a lack of information of the number of scenarios involved. There is no distinction between a hot or cold dose region that occurs in a single or in many scenarios. A solution could be to report the percentage of scenarios in which dose criteria are fulfilled, as well as the scenario average (as done in this work) to reduce sensitivity to single, unfavourable, scenarios.
Although the effect of non-rigid deformations and rotations was not explicitly taken into account, high correlations can be expected with setup and range uncertainties. Our clinical experience is that IMPT plans that were optimised and evaluated to be robust against setup/range errors were usually robust against non-rigid anatomical changes seen on repeat CT scans. Nevertheless, the described method can easily be extended to explicitly include repeated CTs and 4DCT scans to account for anatomical changes and breathing motion [42] . Further developments are to remove the approximation of random setup errors as a systematic error and introduce explicit dose calculations of fractionated, probabilistic treatment scenario sets. This would improve accuracy but requires speedups for clinical routine usage [43, 44] . Finally, a probabilistic approach is a logical development towards a higher goal of robustness evaluation in terms of expected biological outcome.
In conclusion, to the best of our knowledge, the presented Dutch consensus of robustness evaluation is the first to provide comparable robustness of photon and proton treatments for planning comparison, and is in use in daily clinical practice. Centres that clinically introduce robustness evaluation should consider cal- ibration of acceptance criteria against historic treatments to avoid introduction of systematic changes in treatments.
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